Fibril formation and toxicity of the non-amyloidogenic rat amylin peptide

Micron

Volumn 44, Issue 1, 2013, Pages 246-253

  Milton, Nathaniel G N ^a   Harris, J Robin ^b,c  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Amylin; Catalase; Congo red; Fibril; Islet; Rat

Indexed keywords

AMYLIN; CATALASE; CONGO RED; FIBRIL; ISLET;

AZO DYES; CELL CULTURE; GLYCOPROTEINS; PEPTIDES; RATS; TOXICITY;

RAT CONTROL;

AMYLIN; AMYLOID; AMYLOID PROTEIN; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CALCITONIN[8-32][30 ASPARAGINE 32 TYROSINAMIDE]; CATALASE; NEUROPROTECTIVE AGENT; PEPTIDE CHLOROMETHYL KETONE; PEPTIDE FRAGMENT;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PANCREAS ISLET; RAT; TRANSMISSION ELECTRON MICROSCOPY;

AMINO ACID CHLOROMETHYL KETONES; AMYLOID; AMYLOIDOGENIC PROTEINS; ANIMALS; CATALASE; CELLS, CULTURED; HUMANS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS;

RATTUS;

EID: 84870679109     PISSN: 09684328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.micron.2012.07.001     Document Type: Article

References (70)

1. Abedini A., Raleigh D.P. The role of His-18 in amyloid formation by human islet amyloid polypeptide. Biochemistry 2005, 44:16284-16291.
2. Abedini A., Raleigh D.P. Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP. Journal of Molecular Biology 2006, 355:274-281.
3. Andreasen M., Nielsen S.B., Mittag T., Bjerring M., Nielsen J.T., Zhang S., Nielsen E.H., Jeppesen M., Christiansen G., Besenbacher F., Dong M., Nielsen N.C., Skrydstrup T., Otzen D.E. Modulation of fibrillation of hIAPP core fragments by chemical modification of the peptide backbone. Biochimica et Biophysica Acta 2012, 1824:274-285.
4. Binger K.J., Pham C.L.L., Wilson L.M., Bailey M.F., Lawrence L.J., Schuck P., Howlett G.J. Apolipoprotein C-II amyloid fibrils assemble via a reversible pathway that includes fibril breaking and rejoining. Journal of Molecular Biology 2008, 376:1116-1129.
5. Borders C.L., Riordan J.F. An essential arginyl residue at the nucleotide binding site of creatine kinase. Biochemistry 1975, 14:4699-4704.
6. Brender J.R., Dürr U.H.N., Heyl D., Budarapu M.B., Ramamoorthy A. Membrane fragmentation by an amyloidogenic fragment of human islet amyloid polypeptide detected by solid-state NMR spectroscopy of membrane nanotubes. Biochimica et Biophysica Acta 2007, 1768:2026-2029.
7. Brender J.R., Hartman K., Nanga R.P.R., Popovych N., de La Salud Bea R., Vivekanandan S., Marsh E.N.G., Ramamoorthy A. Role of zinc in human islet amyloid polypeptide aggregation. Journal of the American Chemical Society 2010, 132:8973-8983.
8. Brender J.R., Hartman K., Reid K.R., Kennedy R.T., Ramamoorthy A. A single mutation in the nonamyloidogenic region of islet amyloid polypeptide greatly reduces toxicity. Biochemistry 2008, 47:12680-12688.
9. Brender J.R., Lee E.L., Cavitt M.A., Gafni A., Steel D.G., Ramamoorthy A. Amyloid fiber formation and membrane disruption are separate processes localized in two distinct regions of IAPP, the type-2-diabetes-related peptide. Journal of the American Chemical Society 2008, 130:6424-6429.
10. Brender J.R., Salamekh S., Ramamoorthy A. Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective. Accounts of Chemical Research 2012, 45:454-462.
11. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
12. Buxbaum J.N., Linke R.P. A molecular history of the amyloidoses. Journal of Molecular Biology 2012, 421:142-159.
13. Chang L.-S., Wu P.-F., Liou J.-C., Chiang-Lin W.-H., Yang C.-C. Chemical modification of arginine residues of Notechis scutatus scutatus notexin. Toxicon 2004, 44:491-497.
14. Chargé S.B., de Koning E.J., Clark A. Effect of pH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Biochemistry 1995, 34:14588-14593.
15. Cheng B., Gong H., Li X., Sun Y., Zhang X., Chen H., Liu X., Zheng L., Huang K. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochemical and Biophysical Research Communications 2012, 419:495-499.
16. Clark A., Nilsson M.R. Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes?. Diabetologia 2004, 47:157-169.
17. Eisenberg D., Jucker M. The amyloid state of proteins in human diseases. Cell 2012, 148:1188-1203.
18. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. Journal of Molecular Biology 2007, 365:1337-1349.
19. Goldsbury C., Kistler J., Aebi U., Arvinte T., Cooper G.J. Watching amyloid fibrils grow by time-lapse atomic force microscopy. Journal of Molecular Biology 1999, 285:33-39.
20. Götz J., Ittner L.M., Lim Y.-A. Common features between diabetes mellitus and Alzheimer's disease. Cellular and Molecular Life Sciences 2009, 66:1321-1325.
21. Green J., Goldsbury C., Mini T., Sunderji S., Frey P., Kistler J., Cooper G., Aebi U. Full-length rat amylin forms fibrils following substitution of single residues from human amylin. Journal of Molecular Biology 2003, 326:1147-1156.
22. Guérin G., Wang H., Manners I., Winnik M.A. Fragmentation of fiberlike structures: sonication studies of cylindrical block copolymer micelles and behavioral comparisons to biological fibrils. Journal of the American Chemical Society 2008, 130:14763-14771.
23. Habib L.K., Lee M.T.C., Yang J. Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity. Journal of Biological Chemistry 2010, 285:38933-38943.
24. Hettiarachchi M., Chalkley S., Furler S.M., Choong Y.S., Heller M., Cooper G.J., Kraegen E.W. Rat amylin-(8-37) enhances insulin action and alters lipid metabolism in normal and insulin-resistant rats. American Journal of Physiology 1997, 273:E859-E867.
25. Jaikaran E.T., Higham C.E., Serpell L.C., Zurdo J., Gross M., Clark A., Fraser P.E. Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. Journal of Molecular Biology 2001, 308:515-525.
26. Jhamandas J.H., Li Z., Westaway D., Yang J., Jassar S., MacTavish D. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. American Journal of Pathology 2011, 178:140-149.
27. Jhamandas J.H., MacTavish D. β-Amyloid protein (Aβ) and human amylin regulation of apoptotic genes occurs through the amylin receptor. Apoptosis 2012, 17:37-47.
28. Karran E., Mercken M., Strooper B.D. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Reviews: Drug Discovery 2011, 10:698-712.
29. Kawahara M., Kuroda Y., Arispe N., Rojas E. Alzheimer's beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. Journal of Biological Chemistry 2000, 275:14077-14083.
30. Klunk W.E., Jacob R.F., Mason R.P. Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Analytical Biochemistry 1999, 266:66-76.
31. Law E., Lu S., Kieffer T.J., Warnock G.L., Ao Z., Woo M., Marzban L. Differences between amyloid toxicity in alpha and beta cells in human and mouse islets and the role of caspase-3. Diabetologia 2010, 53:1415-1427.
32. Leffert J.D., Newgard C.B., Okamoto H., Milburn J.L., Luskey K.L. Rat amylin: cloning and tissue-specific expression in pancreatic islets. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:3127-3130.
33. Li L.-M., Liu Q.-H., Qiao J.-T., Zhang C. Abeta(31-35)-induced neuronal apoptosis is mediated by JNK-dependent extrinsic apoptosis pathway. Neuroscience Bulletin 2009, 25:361-366.
34. Li X.-L., Chen T., Wong Y.-S., Xu G., Fan R.-R., Zhao H.-L., Chan J.C.N. Involvement of mitochondrial dysfunction in human islet amyloid polypeptide-induced apoptosis in INS-1E pancreatic beta cells: an effect attenuated by phycocyanin. The International Journal of Biochemistry & Cell Biology 2011, 43:525-534.
35. Lim Y.-A., Ittner L.M., Lim Y.L., Götz J. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Letters 2008, 582:2188-2194.
36. Lim Y.-A., Rhein V., Baysang G., Meier F., Poljak A., Raftery M.J., Guilhaus M., Ittner L.M., Eckert A., Götz J. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 2010, 10:1621-1633.
37. Luca S., Yau W.-M., Leapman R., Tycko R. Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR. Biochemistry 2007, 46:13505-13522.
38. Lutz T.A. Control of energy homeostasis by amylin. Cellular and Molecular Life Sciences 2012, 69:1947-1965.
39. Madine J., Jack E., Stockley P.G., Radford S.E., Serpell L.C., Middleton D.A. Structural insights into the polymorphism of amyloid-like fibrils formed by region 20-29 of amylin revealed by solid-state NMR and X-ray fiber diffraction. Journal of the American Chemical Society 2008, 130:14990-15001.
40. Mao X.-B., Wang C.-X., Wu X.-K., Ma X.-J., Liu L., Zhang L., Niu L., Guo Y.-Y., Li D.-H., Yang Y.-L., Wang C. Beta structure motifs of islet amyloid polypeptides identified through surface-mediated assemblies. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:19605-19610.
41. Mattson M.P., Goodman Y. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Research 1995, 676:219-224.
42. McCluskey J.T., Hamid M., Guo-Parke H., McClenaghan N.H., Gomis R., Flatt P.R. Development and functional characterization of insulin-releasing human pancreatic beta cell lines produced by electrofusion. Journal of Biological Chemistry 2011, 286:21982-21992.
43. Middleton C.T., Marek P., Cao P., Chiu C.-C., Singh S., Woys A.M., de Pablo J.J., Raleigh D.P., Zanni M.T. Two-dimensional infrared spectroscopy reveals the complex behaviour of an amyloid fibril inhibitor. Nature Chemistry 2012, 4:355-360.
44. Milardi D., Sciacca M.F.M., Pappalardo M., Grasso D.M., La Rosa C. The role of aromatic side-chains in amyloid growth and membrane interaction of the islet amyloid polypeptide fragment LANFLVH. European Biophysics Journal 2011, 40:1-12.
45. Milton N.G.N. Amyloid-beta binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochemical Journal 1999, 344(Pt 2):293-296.
46. Milton N.G.N. Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer's amyloid-beta peptide. Neurotoxicology 2001, 22:767-774.
47. Milton N.G.N. Amyloid-β phosphorylation. Cell Biology Protocols 2006, 364-368. John Wiley & Sons Ltd., Chichester, England. J.R. Harris, J.M. Graham, D. Rickwood (Eds.).
48. Milton N.G.N. Homocysteine inhibits hydrogen peroxide breakdown by catalase. The Open Enzyme Inhibition Journal 2008, 1:34-41.
49. Milton, N.G.N., Chilumuri, A., Rocha-Ferreira, E., Nercessian, A.N., Ashioti, M., 2012. Kisspeptin prevention of amyloid-β peptide neurotoxicity in vitro. ACS Chemical Neuroscience, in press. doi:10.1021/cn300045d.
50. Milton N.G.N., Harris J.R. Polymorphism of amyloid-beta fibrils and its effects on human erythrocyte catalase binding. Micron 2009, 40:800-810.
51. Milton N.G.N., Harris J.R. Human islet amyloid polypeptide fibril binding to catalase: a transmission electron microscopy and microplate study. TheScientificWorldJournal 2010, 10:879-893.
52. Milton N.G.N., Mayor N.P., Rawlinson J. Identification of amyloid-beta binding sites using an antisense peptide approach. Neuroreport 2001, 12:2561-2566.
53. Minaki H., Sasaki K., Honda H., Iwaki T. Prion protein oligomers in Creutzfeldt-Jakob disease detected by gel-filtration centrifuge columns. Neuropathology 2009, 29:536-542.
54. Nanga R.P.R., Brender J.R., Vivekanandan S., Ramamoorthy A. Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment. Biochimica et Biophysica Acta 2011, 1808:2337-2342.
55. Nanga R.P.R., Brender J.R., Xu J., Hartman K., Subramanian V., Ramamoorthy A. Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy. Journal of the American Chemical Society 2009, 131:8252-8261.
56. Nanga R.P.R., Brender J.R., Xu J., Veglia G., Ramamoorthy A. Structures of rat and human islet amyloid polypeptide IAPP (1-19) in micelles by NMR spectroscopy. Biochemistry 2008, 47:12689-12697.
57. Patil S.M., Mehta A., Jha S., Alexandrescu A.T. Heterogeneous amylin fibril growth mechanisms imaged by total internal reflection fluorescence microscopy. Biochemistry 2011, 50:2808-2819.
58. Patthy L., Smith E.L. Reversible modification of arginine residues. Application to sequence studies by restriction of tryptic hydrolysis to lysine residues. Journal of Biological Chemistry 1975, 250:557-564.
59. Quan L., Cao Q., Li Z., Li N., Li K., Liu F. Highly efficient and low-cost purification of lysozyme: a novel tris(hydroxymethyl)aminomethane immobilized affinity column. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2009, 877:594-598.
60. Ritzel R.A., Jayasinghe S., Hansen J.B., Sturis J., Langen R., Butler P.C. Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regulatory Peptides 2010, 165:158-162.
61. Ritzel R.A., Meier J.J., Lin C.-Y., Veldhuis J.D., Butler P.C. Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets. Diabetes 2007, 56:65-71.
62. Salamekh S., Brender J.R., Hyung S.-J., Nanga R.P.R., Vivekanandan S., Ruotolo B.T., Ramamoorthy A. A two-site mechanism for the inhibition of IAPP amyloidogenesis by zinc. Journal of Molecular Biology 2011, 410:294-306.
63. Salamone S.J., Jordan F. Synthesis of 9-(3,4-dioxopentyl)hypoxanthine, the first arginine-directed purine derivative: an irreversible inactivator for purine nucleoside phosphorylase. Biochemistry 1982, 21:6383-6388.
64. Sandberg M.K., Al-Doujaily H., Sharps B., Clarke A.R., Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011, 470:540-542.
65. Smith P.E.S., Brender J.R., Ramamoorthy A. Induction of negative curvature as a mechanism of cell toxicity by amyloidogenic peptides: the case of islet amyloid polypeptide. Journal of the American Chemical Society 2009, 131:4470-4478.
66. Stefani, M., 2012. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits. Progress in Neurobiology, in press. doi:10.1016/j.pneurobio.2012.03.002.
67. Suckau D., Mak M., Przybylski M. Protein surface topology-probing by selective chemical modification and mass spectrometric peptide mapping. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:5630-5634.
68. Trikha S., Jeremic A.M. Clustering and internalization of toxic amylin oligomers in pancreatic cells require plasma membrane cholesterol. Journal of Biological Chemistry 2011, 286:36086-36097.
69. Westermark P., Engström U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:5036-5040.
70. Zagorski M.G., Yang J., Shao H., Ma K., Zeng H., Hong A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods in Enzymology 1999, 309:189-204.